Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides (2015)
Sequence: Stearoyl-AGYLLGKKINLKALAALAKKIL-NH2
PMO (phosphorodiamidate morpholino oligonucleotide; splice-switching)
| Experiment Id | EXP000999 |
|---|---|
| Paper | Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides |
| Peptide | PF6 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Formulated as nanoparticles; XLA luc reporter assay in U2OS stable cells |
| Rna Concentration | PMO 125–500 nM (U2OS luc reporter) |
| Mixing Ratio | PF6:PMO molar ratio (MR) 5:1 (reported); dose series 125–500 nM |
| Formulation Format | noncovalent lipopeptide/PMO nanoparticles (co-incubation; complex formation) |
| Formulation Components | PF6 + PMO XLA (BTK intron reporter splice correction); 5'-CTACAGAGTTCTCAGGATGTAAGCA-3' |
| Size Nm | 100.00 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | U2OS stable luciferase reporter (BTK intron XLA model); SMA type I fibroblasts GM03813; H2K mdx myotubes + healthy H2K myotubes |
| Animal Model | |
| Administration Route | |
| Output Type | in vitro splice switching (RT-PCR exon inclusion/skipping; luc reporter splice correction) |
| Output Value | Dose-dependent splice correction of luciferase reporter (increased corrected luc band vs naked PMO). |
| Output Units | |
| Output Notes | Splice correction assessed by RT-PCR band shift in BTK intron luc reporter system; NTA showed ~100 nm particles. |
| Toxicity Notes | Myotube viability (MTS): no toxicity at working concentration (~5 µM peptide). St-RXR4 showed toxicity at 40 µM (without PMO). |
| Curation Notes |